Does Entresto Affect Heart Rate?

Entresto (sacubitril/valsartan) does not directly target heart rate the way beta-blockers or ivabradine do, and most clinical data show that resting heart rate stays essentially unchanged after starting the drug. That said, Entresto does influence the nervous system pathways that regulate heart rhythm, and some patients notice subtle shifts in how their heart behaves at rest or during activity. The relationship between Entresto and heart rate is more interesting than a simple “no effect” would suggest.

What Entresto Actually Does in the Body

Entresto combines two active components. One is sacubitril, which blocks an enzyme called neprilysin. Neprilysin normally breaks down several beneficial peptides that help blood vessels relax and reduce fluid retention. By blocking neprilysin, sacubitril lets those peptides stick around longer, easing the workload on the heart. The other component is valsartan, which blocks a receptor in a hormonal system that constricts blood vessels and raises blood pressure. Together, the two ingredients lower blood pressure, reduce strain on the heart, and slow the progression of heart failure.¹

Neither component was designed to speed up or slow down the heart’s electrical pacemaker. That distinguishes Entresto from drugs like ivabradine, which specifically targets the electrical channels in the heart’s natural pacemaker to slow the rate, and from beta-blockers, which block adrenaline signals that drive the heart to beat faster. In short, heart rate is not Entresto’s primary lever. But the body’s systems are interconnected, and a drug that reshapes how your cardiovascular system handles stress can still influence heart rate indirectly.

What the Clinical Data Show About Resting Heart Rate

The most direct evidence comes from studies that measured heart rate before and after patients started sacubitril/valsartan. In a pilot study of heart failure patients with reduced pumping ability, researchers recorded heart rate and blood pressure at baseline and again two months after starting the drug. Heart rate did not change significantly during that period.² Separately, the valsartan component alone has been studied in hypertension and was found not to affect resting heart rate, a finding that held even when compared head-to-head with a calcium-channel blocker that did raise it.³

Registry data from Sweden paint a similar picture. In a large cohort of over 12,000 heart failure patients, average resting heart rate hovered around 71 beats per minute, and baseline heart rate did not meaningfully distinguish who eventually started sacubitril/valsartan from who did not.⁴ In the large PARADIGM-HF trial, higher resting heart rate was identified as a predictor of needing a dose reduction, but the drug itself was not reported to systematically push heart rate up or down.⁵

So the short version for anyone watching their pulse after starting Entresto: the drug is unlikely to produce a noticeable change in resting heart rate on its own. If your resting rate does change substantially, it is worth investigating other causes, including dose adjustments to other medications you may be taking alongside it.

Heart Rate During Exercise

For many people with heart failure, how the heart responds during physical activity matters as much as the resting number. A condition called chronotropic incompetence, where the heart cannot speed up adequately during exertion, is common in heart failure and limits exercise tolerance. A study that tracked patients through the full dose-escalation process of sacubitril/valsartan, from the starting dose up to the target dose, found that peak heart rate during exercise testing did not change at any dose level. At baseline, peak heart rate averaged about 109 beats per minute, and by the end of the study it was about 111, a difference that was not statistically meaningful.⁶

What did improve, though, was exercise capacity itself. Patients were able to do more work during testing, and their oxygen consumption improved, even at sub-target doses. The exercise gains appear to come from improved cardiac output and more efficient oxygen delivery rather than from the heart simply beating faster. In practical terms, if you are on Entresto and feel you can walk farther or climb stairs more easily, the improvement is real but it is not because your heart rate changed. The heart is pumping more effectively with each beat rather than compensating by beating more often.

How Entresto Shifts the Nervous System Behind Heart Rate

Here is where the story gets more nuanced. Even though resting heart rate numbers do not change dramatically, Entresto appears to reshape the underlying nervous system balance that governs heart rate. In heart failure, the sympathetic nervous system, the “fight or flight” branch, is chronically overactive. This overdrive contributes to faster heart rates, irregular rhythms, and progressive damage to the heart muscle.

The pilot study mentioned earlier used a specialized technique to directly measure sympathetic nerve firing in the leg. After two months on sacubitril/valsartan, sympathetic nerve burst frequency dropped from about 43 bursts per minute to 36, and the proportion of heartbeats accompanied by a sympathetic burst fell from about 68 per 100 heartbeats to 55. These are substantial reductions in the body’s stress signaling, yet heart rate and blood pressure stayed the same.⁷

This apparent paradox, less sympathetic drive but no heart rate drop, likely reflects the fact that heart rate in these patients is influenced by many inputs simultaneously. When sympathetic activity decreases, the parasympathetic branch (the “rest and digest” side) may strengthen, and the two shifts can offset each other in terms of the net rate. One study found exactly that pattern: after starting sacubitril/valsartan, markers of parasympathetic tone increased, heart rate variability improved, and resting heart rate decreased modestly.⁸ The researchers attributed part of Entresto’s survival benefit to this rebalancing of the autonomic nervous system.

The practical takeaway is that Entresto may be doing helpful things to the systems that control heart rate even when your pulse stays the same on a wrist monitor. A heart that is under less sympathetic stress and more parasympathetic protection is a heart that is less prone to dangerous rhythms, even if its average rate has not budged.

Effects on Dangerous Heart Rhythms

The autonomic rebalancing described above appears to translate into measurable protection against life-threatening arrhythmias. In a study of heart failure patients with implanted defibrillators, the burden of dangerous fast rhythms from the lower chambers dropped substantially after starting sacubitril/valsartan. The number of patients experiencing these episodes fell from 19 to 10, and the total episode count dropped from 51 to 14. Shorter, non-sustained bursts of fast rhythm also decreased.⁹

A separate matched analysis compared heart failure patients on sacubitril/valsartan against those on older medications and found that the sacubitril/valsartan group had a roughly 60% lower rate of needing their defibrillator to fire or deliver anti-tachycardia pacing.¹⁰ Fewer shocks means fewer dangerous rhythm episodes in the first place, which lines up with the sympathetic calming effect. This is clinically meaningful for patients with defibrillators: the device is a safety net for sudden cardiac arrest, and needing it less frequently is a concrete sign that the underlying electrical stability of the heart has improved.

The reduction in arrhythmias happened alongside improvements in the heart’s structure, specifically a reversal of the enlargement and weakening that characterize heart failure. This “reverse remodeling” likely contributes independently to fewer arrhythmias, because a less stretched, less scarred heart generates more stable electrical signals.

Entresto and Atrial Fibrillation

Atrial fibrillation, the most common sustained abnormal rhythm, deserves separate attention because it directly drives heart rate. During atrial fibrillation, the upper chambers fire chaotically and the ventricles respond with an irregular, often fast pulse. A meaningful share of heart failure patients also have atrial fibrillation, and any drug that influences one condition often affects the other.

Early data suggest that sacubitril/valsartan may help maintain a normal rhythm after electrical cardioversion, the procedure that resets the heart back to its regular beat. In one study, only about 25% of patients on sacubitril/valsartan had their atrial fibrillation come back within 30 days, compared with about 52% of patients not on the drug. After adjusting for other factors, sacubitril/valsartan use was independently associated with a roughly 65% lower chance of the cardioversion failing.¹¹

Another study looked at atrial fibrillation recurrence after catheter ablation and found a numerical decrease in the sacubitril/valsartan group compared with valsartan alone, about 9% versus 16%, though this difference did not reach statistical significance given the sample size. The researchers noted that sacubitril/valsartan was superior at reducing structural changes in the atria that predispose to fibrillation.¹² The evidence here is promising but still early. If Entresto does help prevent atrial fibrillation recurrence, one indirect consequence would be fewer episodes of rapid, irregular heart rates, even though the drug is not lowering rate through the conventional pharmacological route.

Why Entresto Is Almost Always Paired with Heart-Rate-Lowering Drugs

In practice, very few patients take Entresto as their only heart medication. Standard heart failure treatment involves layering multiple drugs, each addressing a different aspect of the disease. Beta-blockers, which directly slow heart rate and reduce the heart’s demand for oxygen, are a cornerstone of this regimen. One study on metoprolol succinate combined with Entresto noted that metoprolol reduces blood pressure and heart rate, but is not effective enough on its own for congestive heart failure.¹³ The combination makes sense: Entresto handles neurohormonal remodeling and fluid balance, while the beta-blocker handles rate control and sympathetic blockade.

This layering matters for interpreting your own experience on Entresto. If your heart rate drops after you start Entresto, it could easily be because your doctor simultaneously adjusted your beta-blocker dose, added ivabradine, or made another medication change. Entresto is rarely introduced in isolation, so attributing a heart rate change specifically to it versus the overall medication adjustment can be tricky without careful tracking.

Some patients worry about additive effects, wondering whether Entresto plus a beta-blocker will slow their heart rate too much. The evidence suggests this is generally not a concern with Entresto itself, since its heart rate effect is minimal. The more relevant risk factors for excessive slowing are beta-blocker dose and, if used, ivabradine dose. If you feel dizzy, lightheaded, or excessively fatigued, your doctor will likely look at those other medications first.

When Heart Rate Changes Should Prompt a Conversation

Even though Entresto does not reliably change heart rate, certain patterns are worth flagging with your doctor. A sudden increase in resting heart rate, say going from the mid-60s to the mid-80s or higher without an obvious reason like illness or dehydration, can be an early sign that heart failure is worsening or that atrial fibrillation has developed. This is true regardless of what medications you are on, but heart failure patients tend to monitor their pulse more closely, and it is worth knowing what to watch for.

Conversely, a very low heart rate (below about 50 beats per minute at rest) with symptoms like dizziness, confusion, or fainting warrants prompt attention. This is more likely to be caused by beta-blockers or other rate-controlling drugs than by Entresto, but the clinical picture is what matters, not which pill gets the blame. The key point is that Entresto neither raises nor lowers your heart rate enough to mask or explain meaningful changes. If something shifts noticeably, look elsewhere in your medication list or your overall health for the cause.

Heart Rate Variability as a Subtler Marker

Many consumer wearables now report heart rate variability alongside average heart rate. Heart rate variability measures the tiny fluctuations in timing between consecutive heartbeats, and higher variability generally reflects healthier autonomic function. In heart failure, variability tends to be low because the sympathetic nervous system is dominant and the parasympathetic side is suppressed.

Research on sacubitril/valsartan has found improvements in several heart rate variability metrics, including increased deceleration capacity and broader beat-to-beat fluctuation, after initiating the drug.¹⁴ If you are tracking heart rate variability with a smartwatch or fitness band, you might notice a gradual upward trend after starting Entresto even if your average heart rate stays flat. The improvement in variability aligns with the sympathetic calming and parasympathetic strengthening described earlier, and it is considered a favorable prognostic sign in heart failure. That said, consumer wearable measurements are much noisier than the clinical-grade monitors used in studies, so small changes on a watch should not drive medical decisions on their own.

Individual Variation and Why Your Experience May Differ

Population averages can obscure meaningful individual responses. While the group-level data consistently show no significant heart rate change from sacubitril/valsartan, individual patients exist along a distribution. Some may experience a modest decrease in resting rate, particularly those who had pronounced sympathetic overdrive at baseline, as the autonomic rebalancing effect may be more noticeable in them. Others on multiple medications may see rate changes that are difficult to attribute to any single drug.

Age, kidney function, the severity of heart failure, and the specific combination of other medications all interact. In the PARADIGM-HF analysis, patients who needed dose reductions tended to be older, have worse kidney function, and have higher baseline heart rates.¹⁵ Those dose reductions were driven primarily by low blood pressure and kidney changes, not by heart rate problems, which further reinforces that heart rate is not a dose-limiting factor with this drug in the way it can be with beta-blockers.

If you are someone who closely monitors your pulse and notices a change after starting Entresto, the change is real for you, but it is more likely a downstream result of improved cardiac function, better fluid balance, or co-medication adjustments than a direct pharmacological effect of sacubitril/valsartan on your heart’s pacemaker cells. Understanding the distinction helps avoid unnecessary alarm or unnecessary medication changes when the cause lies elsewhere.